CCA
CVKD icon

Cygnus Capital Advisors’s Cadrenal Therapeutics CVKD Stock Holding History

Cygnus Capital Advisors’s Portfolio CVKD Stock Details CVKD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,492
Closed -$8K – 80
2026
Q1 		$8K Buy
+1,492
New +$10.5K 0.01% 99

Other funds holding CVKD

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CA
Clearstead Advisors Cleveland, Ohio $10.6B AUM 24.87% 1-Year Est. Return

Cygnus Capital Advisors's CVKD Position: Q2 2026 in Review

Cygnus Capital Advisors sold out of Cadrenal Therapeutics (CVKD) in Q2 2026, closing a stake of 1,492 shares — an estimated $8K sold.

Cygnus Capital Advisors first reported a position in CVKD in Q1 2026 and held it in 1 quarter. The position peaked at $8K in Q1 2026. 19 funds tracked by Wall St. Rank hold CVKD as of Q2 2026.

  • Cygnus Capital Advisors reported no remaining Cadrenal Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 1,492 Cadrenal Therapeutics shares in Q2 2026, an estimated $8K.
  • Cygnus Capital Advisors first reported a position in Cadrenal Therapeutics in Q1 2026 and held it in 1 quarter.
  • Cygnus Capital Advisors's Cadrenal Therapeutics position peaked at $8K in Q1 2026.
  • 19 funds tracked by Wall St. Rank held Cadrenal Therapeutics as of Q2 2026.

Based on Cygnus Capital Advisors's 13F filing for Q2 2026, filed 3 Sep 2026.